Completed PHASE2 INTERVENTIONAL 3-arm NCT05671835

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Sponsor: Tvardi Therapeutics, Incorporated

Conditions Idiopathic Pulmonary Fibrosis

Interventions Placebo TTI-101

Updated 22 times since 2023 Last updated: Sep 26, 2025 Started: May 15, 2023 Primary completion: Aug 14, 2025 Completion: Aug 14, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05671835, this PHASE2 trial focuses on Idiopathic Pulmonary Fibrosis and remains completed. Sponsored by Tvardi Therapeutics, Incorporated, it has been updated 22 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

22 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE2

▶ Show 17 earlier versions

Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
May 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2023 — Apr 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tvardi Therapeutics, Incorporated

Data source: Tvardi Therapeutics, Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Bethlehem, United States , Birmingham, United States , Brooklyn, United States , Charleston, United States , Chesterfield, United States , Chicago, United States , Clearwater, United States , Dallas, United States and 16 more locations